/manager/Index ${session.getAttribute("locale")} 5 What's in a name? 'Non-coeliac gluten or wheat sensitivity': controversies and mechanisms related to wheat and gluten causing gastrointestinal symptoms or disease /manager/Repository/uon:34904 Wed 22 May 2019 12:08:39 AEST ]]> What causes functional gastrointestinal disorders?: A proposed disease model /manager/Repository/uon:37124 Wed 19 Aug 2020 10:39:42 AEST ]]> Novel concepts in the pathophysiology and treatment of functional dyspepsia /manager/Repository/uon:37123 Wed 19 Aug 2020 10:35:40 AEST ]]> Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method /manager/Repository/uon:37120 Wed 19 Aug 2020 09:43:44 AEST ]]> Hill classification is superior to the axial length of a hiatal hernia for assessment of the mechanical anti-reflux barrier at the gastroesophageal junction /manager/Repository/uon:24743 Wed 11 Apr 2018 16:33:09 AEST ]]> Dysmotility symptoms are independently associated with weight change: a population-based study of Australian adults /manager/Repository/uon:26276 Wed 11 Apr 2018 16:11:50 AEST ]]> Factor analysis identifies subgroups of constipation /manager/Repository/uon:12371 Wed 11 Apr 2018 16:11:06 AEST ]]> Endoscopic full-thickness biopsy of the gastric wall with defect closure by using an endoscopic suturing device: survival porcine study /manager/Repository/uon:21656 Wed 11 Apr 2018 16:05:51 AEST ]]> Prevalence and risk factors of gastrointestinal disorders in patients with rheumatoid arthritis: results from a population-based survey in Olmsted County, Minnesota /manager/Repository/uon:12381 Wed 11 Apr 2018 15:31:41 AEST ]]> Functional dyspepsia: new insights into pathogenesis and therapy /manager/Repository/uon:24776 Helicobacter pylori infection is considered to be causally linked to dyspepsia although only a minority will respond to eradication. In those with EPS, acid suppression therapy is a first line therapy; consider a H₂ blocker even if proton pump inhibitor fails. In PDS, a prokinetic is preferred. Second line therapy includes administration of a tricyclic antidepressant in low doses, or mirtazapine, but not a selective serotonin reuptake inhibitor.]]> Wed 11 Apr 2018 13:53:18 AEST ]]> Acid and non-acid reflux in patients refractory to proton pump inhibitor therapy: is gastroparesis a factor? /manager/Repository/uon:22234 4, respectively), the duration of acid and non-acid reflux in a 24-h period, and the number of reflux episodes lasting longer than 5 min. Results: No statistical difference was seen between the patients with GP and controls with respect to the total number or duration of acid reflux events, total number and duration of non-acid reflux events or the duration of longest reflux episodes. The number of non-acid reflux episodes with a pH > 7 was higher in subjects with GP than in controls. In addition, acid reflux episodes were more prolonged (lasting longer than 5 min) in the GP patients than in controls; however, these values did not reach statistical significance. Thirty-five patients had recorded symptoms during the 24 h study and of the 35 subjects, only 9% (n = 3) had a positive symptom association probability (SAP) for acid/non-acid reflux and 91% had a negative SAP. Conclusion: The evaluation of patients with a documented history of GP did not show an association between GP and more frequent episodes of non-acid reflux based on MII-pH testing.]]> Wed 11 Apr 2018 12:43:08 AEST ]]> The study on the epidemiology of psychological, alimentary health and nutrition (SEPAHAN): overview of methodology /manager/Repository/uon:21353 Wed 11 Apr 2018 11:27:32 AEST ]]> Irritable bowel syndrome /manager/Repository/uon:21224 w1 there have been some significant developments in terms of synthesis of existing evidence, as well as emerging therapies. We therefore summarise recent systematic reviews, meta-analyses, and randomised controlled trials in order to provide a general update as to how to effectively identify and manage this disorder.]]> Wed 11 Apr 2018 11:11:00 AEST ]]> Functional dyspepsia: advances in diagnosis and therapy /manager/Repository/uon:30721 Helicobacter pylori eradication. Treatment of duodenal eosinophilia is under investigation.]]> Wed 11 Apr 2018 11:07:42 AEST ]]> Predictors of response rates to a long term follow-up mail out survey /manager/Repository/uon:15070 Wed 11 Apr 2018 10:01:02 AEST ]]> Irritable bowel syndrome /manager/Repository/uon:34075 Wed 06 Feb 2019 14:24:00 AEDT ]]> The alignment of dietary intake and symptom-reporting capture periods in studies assessing associations between food and functional gastrointestinal disorder symptoms: A systematic review /manager/Repository/uon:36082 Wed 05 Feb 2020 13:13:07 AEDT ]]> Circulating anti-cytolethal distending toxin B and anti-vinculin antibodies as biomarkers in community and healthcare populations with functional dyspepsia and irritable bowel syndrome /manager/Repository/uon:36083 Wed 05 Feb 2020 13:13:07 AEDT ]]> Follow up on atopy and the gastrointestinal tract: a review of a common association 2018 /manager/Repository/uon:37101 Tue 18 Aug 2020 10:23:42 AEST ]]> Elevated serum tissue transglutaminase antibodies in children with eosinophilic esophagitis /manager/Repository/uon:33176 6× upper limit of normal (ULN) and 4 had >10× ULN. TTG Ab-positive patients were classified as having either potential CD with (n = 3, 16%) and without lymphocytic duodenosis (LD; n = 12, 63%), and no CD (n = 4, 21%) on human leukocyte antigen typing. There was an increase in duodenal eosinophils in patients with elevated TTG Ab (P = 0.01), which remained when patients with LD were excluded (P = 0.018). Of 19 patients with EoE and elevated TTG Ab, 5 responded to elimination diet involving exclusion of wheat, including 2 with a sole wheat trigger and TTG Ab >10× ULN that were CD-associated human leukocyte antigen-negative. Conclusions: Serum TTG Ab was elevated in almost one-quarter of our total EoE cohort, and at least 20% of these patients did not have potential CD, suggesting EoE is a heterogeneous disease with differing immune mechanisms activated in some patients. These findings also support routine esophageal biopsy during upper endoscopy in children with elevated TTG Ab.]]> Tue 11 Sep 2018 12:15:33 AEST ]]> Functional dyspepsia /manager/Repository/uon:25796 Tue 11 Feb 2020 09:19:02 AEDT ]]> Influence of cigarette smoking on the human duodenal mucosa-associated microbiota /manager/Repository/uon:33993 Firmicutes, specifically Streptococcus and Veillonella spp. The relative abundance of the genus Rothia was also observed to be greater in current smokers; while in contrast, levels of Prevotella and Neisseria were lower. The MAM profiles and diversity of previous smokers were observed to be intermediate between current and never smokers. Smoking did not impact the total density of bacteria present on the mucosa. Conclusions: These data indicate the duodenal MAM of current smokers is characterised by reduced bacterial diversity, which is partially but not completely restored in previous smokers. While the precise mechanisms remain to be elucidated, these microbiota changes may in some part explain the adverse effects of smoking on mucosa-associated diseases of the GI tract. Smoking status requires consideration when interpreting MAM data.]]> Tue 03 Sep 2019 17:58:12 AEST ]]> Functional dyspepsia and duodenal eosinophilia: a new model /manager/Repository/uon:33727 Helicobacter pylori (H. pylori) may explain a minority of cases of FD and in the Rome IV criteria H. pylori-associated dyspepsia (defined as symptom relief after eradication therapy) is considered a separate entity. Duodenal inflammation characterized by increased eosinophils and in some cases mast cells, may impair the intestinal barrier. Post-infectious gastroenteritis is now an established risk factor for FD. Other risk factors may include atopy, owning herbivore pets and exposure to antibiotics, together with gastroduodenal microbiome disturbances. Small bowel homing T cells and increased cytokines in the circulation occur in FD, correlating with slow gastric emptying, and a possible association with autoimmune rheumatological disease supports background immune system activation. A genetic predisposition is possible. FD has been linked to psychological disorders, but in some cases psychological distress may be driven by gut mechanisms. Therapeutic options are limited and, aside from responders to H. pylori eradication, provide only modest and temporary relief. Advances in understanding FD may alter clinical practice, and the treatment of duodenal inflammation or microbiome alterations may lead to a cure for a subset of these patients in the future.]]> Thu 13 Dec 2018 15:22:10 AEDT ]]> Early infections and the risk of irritable bowel syndrome: a case-control study /manager/Repository/uon:37067 Thu 13 Aug 2020 12:05:44 AEST ]]> Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts /manager/Repository/uon:36115 Thu 06 Feb 2020 16:38:08 AEDT ]]> Development of a symptom-focused patient-reported outcome measure for functional dyspepsia: the Functional Dyspepsia Symptom Diary (FDSD) /manager/Repository/uon:36113 Thu 06 Feb 2020 15:00:07 AEDT ]]> Identification and validation of functional gastrointestinal disorder subtypes using latent class analysis: a population-based study /manager/Repository/uon:36112 Thu 06 Feb 2020 14:32:06 AEDT ]]> Effects of amitriptyline and escitalopram on sleep and mood in patients with functional dyspepsia /manager/Repository/uon:36111 Thu 06 Feb 2020 14:25:07 AEDT ]]> Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus /manager/Repository/uon:36110 Thu 06 Feb 2020 14:11:06 AEDT ]]> Role of the duodenum in the pathogenesis of functional dyspepsia: a paradigm shift /manager/Repository/uon:36107 Thu 06 Feb 2020 13:57:08 AEDT ]]> Irritable bowel syndrome and functional dyspepsia: what can epidemiology tell us about etiology? /manager/Repository/uon:36108 Thu 06 Feb 2020 13:57:07 AEDT ]]> Wheat intolerance and chronic gastrointestinal symptoms in an Australian population-based study: association between wheat sensitivity, celiac disease and functional gastrointestinal disorders /manager/Repository/uon:36106 Thu 06 Feb 2020 13:43:06 AEDT ]]> Inconsistent symptom clusters for functional gastrointestinal disorders in Asia: is Rome burning? /manager/Repository/uon:36105 Thu 06 Feb 2020 13:29:07 AEDT ]]> Overlap of irritable bowel syndrome and functional dyspepsia in the clinical setting: prevalence and risk factors /manager/Repository/uon:36104 Thu 06 Feb 2020 13:22:09 AEDT ]]> The Nepean Dyspepsia Index is a valid instrument for measuring quality-of-life in functional dyspepsia /manager/Repository/uon:36103 0.5) standardized loadings on their respective latent variables and all reached statistical significance (P<0.0001), supporting their relationships with the hypothesized domains. Convergent validity was strongly supported, with every domain being correlated with multiple external instruments; the majority of correlations were in the range 0.3-0.5 (in absolute values). The items comprising each domain showed good internal consistency, with the lowest value of Chronbach α at 0.80. Scores based on the short form (10-item) version of the NDI correlated strongly with the full 25-item form (tension ρ=0.88, interference ρ=0.94, eat/drink ρ=0.95, knowledge ρ=0.84 and work/study ρ=0.97; all P<0.0001). Conclusion: The NDI is a valid instrument that can be used to measure the disease-specific impact of FD on quality of life.]]> Thu 06 Feb 2020 13:08:06 AEDT ]]> Duodenal pathology in patients with rumination syndrome: duodenal eosinophilia and increased intraepithelial lymphocytes /manager/Repository/uon:36102 Thu 06 Feb 2020 12:12:08 AEDT ]]> Population based study: atopy and autoimmune diseases are associated with functional dyspepsia and irritable bowel syndrome, independent of psychological distress /manager/Repository/uon:36101 Thu 06 Feb 2020 12:05:07 AEDT ]]> Risk factors for upper and lower functional gastrointestinal disorders in Persian Gulf War veterans during and post-deployment /manager/Repository/uon:36100 Thu 06 Feb 2020 11:58:07 AEDT ]]> Evidence for local and systemic immune activation in functional dyspepsia and the irritable bowel syndrome: a systematic review /manager/Repository/uon:36099 Thu 06 Feb 2020 11:37:06 AEDT ]]> Duodenal eosinophilia is associated with functional dyspepsia and new onset gastro-oesophageal reflux disease /manager/Repository/uon:36098 Thu 06 Feb 2020 11:23:06 AEDT ]]> Tangible pathologies in functional dyspepsia /manager/Repository/uon:36097 Helicobacter pylori and other pathophysiological changes, most notably duodenal pathology, namely duodenal eosinophilia, permeability alterations, structural neuronal changes and microbial duodenal dysbiosis. This has led to the idea that FD is a true disease entity and triggers of this condition based on epidemiology studies point towards allergy, immune disorders and infection. Anxiety and depression may precede or follow FD, (brain-gut/gut-brain disorders). Currently most therapies for FD are inadequate but underlying pathology may lead to targeted treatment success as an attainable goal.]]> Thu 06 Feb 2020 09:59:06 AEDT ]]> Functional dyspepsia in the elderly /manager/Repository/uon:36096 Helicobacter pylori pathologies, cancer, coeliac disease, and autoimmune gastritis. Recent research is unraveling pathophysiology beyond symptom-only definitions, focusing on the duodenum with innate immune disturbance (duodenal eosinophilia) and microbial disruption as possible cause. Management of functional dyspepsia includes making a secure diagnosis, treatment with first-line proton pump inhibitors (PPI), then tricyclic antidepressants, and careful choice of prokinetics. Herbal treatments (peppermint oil) and STW-5 have in this age group limited efficacy. Summary: Further studies are needed to define the prevalence of functional dyspepsia in the elderly and of prime importance, to exclude organic disease as a cause for symptoms of dyspepsia.]]> Thu 06 Feb 2020 09:52:07 AEDT ]]> Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis /manager/Repository/uon:12376 2.5 g/day do not appear to lead to higher remission rates.]]> Sat 24 Mar 2018 10:34:56 AEDT ]]> Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture /manager/Repository/uon:12377 Sat 24 Mar 2018 10:34:56 AEDT ]]> Longitudinal direct medical costs associated with constipation in women /manager/Repository/uon:12372 Sat 24 Mar 2018 10:34:56 AEDT ]]> Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review /manager/Repository/uon:12373 Sat 24 Mar 2018 10:34:55 AEDT ]]> Is there a link between H. Pylori and the epidemiology of Crohn's disease? /manager/Repository/uon:31427 Helicobacter pylori (H. pylori) and Crohn's disease (CD). It is possible this could be accounted for by confounders such as antibiotic therapy. Analyzing the geographic distribution of H. pylori and the links with the incidence and prevalence of CD would be an alternative approach to circumvent these confounders. Methods: The literature was searched for studies published between 1990 and 2016 that reported incidence or prevalence data for CD in random population samples in developed countries (GDP per capita > 20,000 USD/year). Corresponding prevalence studies for H. pylori in these same regions were then sought matched to the same time period (±6 years). The association between the incidence and prevalence of CD and H. pylori prevalence rates were assessed before and after adjusting for GDP and life expectancy. Results: A total of 19 CD prevalence and 22 CD incidence studies from 10 European countries, Japan, USA, and Australia with date-matched H. pylori prevalence data were identified. The mean H. pylori prevalence rate was 43.4% (range 15.5-85%), and the mean rates for incidence and prevalence for CD were 6.9 and 91.0/100,000 respectively. The incidence (r = -0.469, p < 0.03) and prevalence (r = -0.527, p = 0.02) of CD was inversely and significantly associated with prevalence of H. pylori infection. Conclusions: Our data demonstrate a significant inverse association between geographic distribution of H. pylori and CD. Thus, it is highly unlikely that the findings of previous case control studies were simply due to confounding factors such as concomitant antibiotic use in CD patients.]]> Sat 24 Mar 2018 08:43:14 AEDT ]]> STW5 (Iberogast) herbal therapy and functional gastrointestinal symptoms /manager/Repository/uon:14112 Sat 24 Mar 2018 08:26:02 AEDT ]]> A link between physician-diagnosed ulcer and anxiety disorders among adults /manager/Repository/uon:13977 Sat 24 Mar 2018 08:24:41 AEDT ]]> Stool characteristics and colonic transit in irritable bowel syndrome: evaluation at two time points /manager/Repository/uon:14578 Sat 24 Mar 2018 08:22:40 AEDT ]]> Increased incidence of eosinophilic esophagitis in children and adults with celiac disease /manager/Repository/uon:12766 =15 eosinophils per high power field and associated symptoms were present. Age-adjusted and sex-adjusted standardized incidence ratios (SIR) with corresponding 95% confidence intervals (CI) were calculated in comparison to published US population-derived incidence data. EoE was diagnosed in 4 children and 10 adults. EoE is more common compared with the general population; SIR for children was 35.6 (95% CI, 9.3-79.0) and for adults 13.1 (95% CI, 6.2-22.5). Overall, the age-adjusted and sex-adjusted SIR was 16.0 (95% CI, 8.7-25.5). The incidence of EoE in our cohort of patients with CD was increased compared with the general population. Coexistent EoE should be considered in patients with CD who have persistent esophageal symptoms.]]> Sat 24 Mar 2018 08:18:21 AEDT ]]> The role of 5-HTT LPR and GNβ3 825C>T polymorphisms and gene–environment interactions in Irritable Bowel Syndrome (IBS) /manager/Repository/uon:12767 T polymorphisms in IBS, and interactions between 5-HTT LPR with life events have been reported in the psychiatric literature, but gene–environment studies in IBS are lacking. Aims: The purpose of this study was to assess the association of two polymorphisms with IBS and age of onset, and whether there are gene–environment interactions with IBS. Methods: Outpatients with IBS and controls completed a validated questionnaire and provided blood for DNA. Comparisons of genotype/allele frequencies between cases and controls were performed with logistic regression. Linear regression was used to evaluate the association between the variants and age of onset. Environmental variables tested included abuse, parental alcohol abuse, parental psychiatric disorders, and gastrointestinal infections. Results: Genotyping was performed in 385 cases and 262 controls with median age of 50 years (range, 18.0–70.0) and 498 (77 %) females. The IBS subtype distribution among cases was: 102 (26 %) D-IBS, 40 (10 %) C-IBS, 125 (32 %) M-IBS, 118 (31 %) other. No association was observed between IBS or age of onset and both variants. Significant interactions were observed between GI infection and the GNβ3 825T allele. For those reporting gastrointestinal infection, the OR for IBS was 3.9 (95 % CI 1.2–12.7) whereas the OR was 0.86 (95 % CI 0.65–1.13) for those without prior infection. Conclusions: There was a significant interaction between the GNβ3 polymorphism and infection in the development of IBS, suggesting that its etiology is the result of a combination of specific genetic and environmental risk factors.]]> Sat 24 Mar 2018 08:18:21 AEDT ]]> Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: a longitudinal population-based study. /manager/Repository/uon:12768 Sat 24 Mar 2018 08:18:21 AEDT ]]> Prevalence of colonic neoplasia and advanced lesions in the normal population: a prospective population-based colonoscopy study /manager/Repository/uon:12776 Sat 24 Mar 2018 08:18:20 AEDT ]]> Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population /manager/Repository/uon:12777 Sat 24 Mar 2018 08:18:20 AEDT ]]> What level of IBS symptoms drives impairment in health-related quality of life in community subjects with irritable bowel syndrome?: are current IBS symptom thresholds clinically meaningful? /manager/Repository/uon:12771 43 and >48) and ‘impaired’ functioning (defined as a score of ≤43 and ≤48), respectively. Psychological variables were assessed via valid self-report. Results: Having ‘more’ versus ‘less’ severe abdominal pain (OR = 9.41; 95% CI 1.17–75.43, P = 0.03) and ‘more’ versus ‘less’ frequent diarrhoea (OR = 2.19; 95% CI 1.13–4.26, P = 0.02) along with increasing age (OR = 1.03; 95% CI 1.01–1.05, P = 0.003) were significant independent predictors of having impairment in physical functioning. In terms of psychological factors, having higher levels of depression (OR = 1.61; 95% CI 1.36–1.91) and somatic distress (OR = 1.17; 95% CI 1.09–1.27) were independently associated with mental and physical impairment, respectively. Conclusion: The current frequency and severity threshold cut-offs for IBS symptoms in the Rome III criteria are associated with a clinically meaningful impairment of quality of life in community subjects with IBS.]]> Sat 24 Mar 2018 08:18:20 AEDT ]]> Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics /manager/Repository/uon:12764 Sat 24 Mar 2018 08:18:20 AEDT ]]> Challenges and lessons learned in conducting comparative-effectiveness trials /manager/Repository/uon:12773 Sat 24 Mar 2018 08:18:20 AEDT ]]> Consensus statements for management of Barrett's Dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process /manager/Repository/uon:12780 Sat 24 Mar 2018 08:18:20 AEDT ]]> Management of noncardiac chest pain in women /manager/Repository/uon:12775 Sat 24 Mar 2018 08:18:20 AEDT ]]> Fecal incontinence: mechanisms and management /manager/Repository/uon:12774 Sat 24 Mar 2018 08:18:20 AEDT ]]> Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis /manager/Repository/uon:12781 90% decrease in mean eosinophil count) was observed in 11 of 15 subjects who received 6 weeks of fluticasone (62%), compared with none of the 15 subjects who received placebo (P < .001), based on intention-to-treat analysis; histologic responses were observed in 68% of subjects who received fluticasone (13 of 19) compared with none of those who received placebo (0 of 15) by per-protocol analysis (P < .001). Intracellular staining for eosinophil-derived neurotoxin was reduced in 81% of subjects who received fluticasone (13 of 16) compared with 8% who received placebo (1 of 13) (P < .001). Dysphagia was reduced in 57% of subjects who received fluticasone (12 of 21) compared with 33% who received placebo (7 of 21) (P = .22) by intention-to-treat analysis; dysphagia was reduced in 63% of patients who received fluticasone (12 of 19) and 47% of those who received placebo (7 of 15) (P = .49) based on per-protocol analysis. Esophageal candidiasis developed in 26% of subjects who received fluticasone (5 of 19), but in none of the subjects in the placebo group (P = .05). Aerosolized, swallowed fluticasone leads to a histologic but not a symptomatic response in adults with EoE.]]> Sat 24 Mar 2018 08:18:19 AEDT ]]> Esophageal diameter is decreased in some patients with eosinophilic esophagitis and might increase with topical corticosteroid therapy /manager/Repository/uon:12769 Sat 24 Mar 2018 08:18:19 AEDT ]]> Excess comorbidity prevalence and cost associated with functional dyspepsia in an employed population /manager/Repository/uon:12779 300,000 employees. Employees with FD were compared to propensity-score-matched employees without FD (controls). Outcome measures included the prevalence, costs, and utilization of health services for comorbid conditions as defined by the Agency for Healthcare Research and Quality (AHRQ) and the odds ratios of having FD from a multivariate model. Results: FD employees (N = 1,669) and a 50:1 matched control cohort (N = 83,450) were compared. Compared to matched controls, FD employees were more likely to have all major diagnostic categories. Moreover, 199/261 of the AHRQ’s specific categories were more common in the FD cohort. Annual medical costs for the FD cohort were greater than for controls in 155/261 (59%) specific categories and significantly greater (P ≤ 0.05) in 76 categories (29%). Similarly, services were greater for 179/261 (69%) specific categories and significantly greater (P ≤ 0.05) in 110 categories (42%). In a multivariate model, esophageal disorders, gastritis and duodenitis, and abdominal pain were the most associated with having FD (odds ratios 3.8, 3.7, and 3.6, respectively). Only hypertension complications and disorders of the teeth and jaw were significantly negatively associated with FD.Conclusion: There is unexplained excess comorbidity associated with FD which may be a major determining factor for excess healthcare services and costs.]]> Sat 24 Mar 2018 08:18:19 AEDT ]]> Factors associated with persistent and nonpersistent chronic constipation, over 20 years /manager/Repository/uon:12778 Sat 24 Mar 2018 08:18:19 AEDT ]]> Spectrum of gastroparesis in children /manager/Repository/uon:12765 Sat 24 Mar 2018 08:18:18 AEDT ]]> An update on irritable bowel syndrome: from diagnosis to emerging therapies /manager/Repository/uon:13297 Sat 24 Mar 2018 08:18:05 AEDT ]]> Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole - results from the STARS II study /manager/Repository/uon:12379 Sat 24 Mar 2018 08:18:00 AEDT ]]> Erosive esophagitis is a risk factor for Barrett's esophagus: a community-based endoscopic follow-up study /manager/Repository/uon:12384 Sat 24 Mar 2018 08:18:00 AEDT ]]> Occurrence of and risk factors for complications after endoscopic dilation in eosinophilic esophagitis /manager/Repository/uon:12380 Sat 24 Mar 2018 08:18:00 AEDT ]]> The role of eosinophils and mast cells in intestinal functional disease /manager/Repository/uon:12382 Sat 24 Mar 2018 08:18:00 AEDT ]]> Prospective diary evaluation of unexplained abdominal pain and bowel dysfunction: a population-based colonoscopy study /manager/Repository/uon:12383 Sat 24 Mar 2018 08:18:00 AEDT ]]> Novel biomarker panel for the irritable bowel syndrome: a diagnostic blood test is promising /manager/Repository/uon:13237 Sat 24 Mar 2018 08:17:36 AEDT ]]> Irritable bowel syndrome: rational therapy /manager/Repository/uon:13490 Sat 24 Mar 2018 08:16:45 AEDT ]]> Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia /manager/Repository/uon:12399 Sat 24 Mar 2018 08:15:46 AEDT ]]> Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis /manager/Repository/uon:12400 Sat 24 Mar 2018 08:15:46 AEDT ]]> Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis /manager/Repository/uon:12402 Sat 24 Mar 2018 08:15:46 AEDT ]]> Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis /manager/Repository/uon:12403 Sat 24 Mar 2018 08:15:46 AEDT ]]> Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study /manager/Repository/uon:12398 1cm with intestinal metaplasia) and IMGEJ (intestinal metaplasia in biopsies from the gastroesophageal junction) from 1976 to 2006 in Olmsted County, MN, were identified using Rochester Epidemiology Project resources. Demographic and clinical data were abstracted from medical records and pathology confirmed by gastrointestinal pathologists. The association of baseline characteristics with overall and progression-free survival was assessed using proportional hazards regression models. Outcome measures were baseline characteristics and overall survival of subjects with IMGEJ compared to those with BE. Results: In all, 487 patients (401 with BE and 86 with IMGEJ) were identified and followed for a median interval of 7 (BE subjects) to 8 (IMGEJ subjects) years. Subjects with BE were older, heavier, reported reflux symptoms more often, and had higher prevalence of advanced neoplasia than those with IMGEJ. No patient with IMGEJ progressed to esophageal adenocarcinoma (EAC) in contrast to BE subjects who had a cumulative risk of progression of 7% at 10 years and increased risk of death from EAC (standardized mortality ratio 9.62). The overall survival of subjects with BE and IMGEJ did not differ from that expected in similar age- and sex-distributed white Minnesota populations. Conclusions: Subjects with IMGEJ appear to have distinct clinical characteristics and substantially lower cancer progression risk compared to those with BE.]]> Sat 24 Mar 2018 08:15:45 AEDT ]]> 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis /manager/Repository/uon:12395 Sat 24 Mar 2018 08:15:45 AEDT ]]> Overlap: irritable bowel syndrome, inflammatory bowel disease, and diverticular disease /manager/Repository/uon:12396 Sat 24 Mar 2018 08:15:45 AEDT ]]> Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis /manager/Repository/uon:12431 Sat 24 Mar 2018 08:15:28 AEDT ]]> Low grade esophageal eosinophilia in adults: an unrecognized part of the spectrum of eosinophilic esophagitis? /manager/Repository/uon:12433 Sat 24 Mar 2018 08:15:28 AEDT ]]> Pathways connecting cognitive behavioral therapy and change in bowel symptoms of IBS /manager/Repository/uon:12435 Sat 24 Mar 2018 08:15:27 AEDT ]]> An evidence-based systematic review on medical therapies for inflammatory bowel disease /manager/Repository/uon:12436 Sat 24 Mar 2018 08:15:27 AEDT ]]> Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis /manager/Repository/uon:12432 Sat 24 Mar 2018 08:15:27 AEDT ]]> Sexual, physical, verbal/emotional abuse and unexplained chest pain /manager/Repository/uon:12374 Sat 24 Mar 2018 08:15:09 AEDT ]]> Meta-analysis: the epidemiology of noncardiac chest pain in the community /manager/Repository/uon:12375 Sat 24 Mar 2018 08:15:09 AEDT ]]> Minimum clinically important difference for the Nepean Dyspepsia Index, a validated quality of life scale for functional dyspepsia /manager/Repository/uon:10527 Sat 24 Mar 2018 08:13:57 AEDT ]]> Functional dyspepsia /manager/Repository/uon:32138 Mon 23 Sep 2019 13:50:35 AEST ]]> A serological diagnosis of coeliac disease is associated with osteoporosis in older Australian adults /manager/Repository/uon:32805 Mon 23 Sep 2019 10:39:48 AEST ]]> Prevalence of hidden gastroparesis in the community: the gastroparesis "iceberg" /manager/Repository/uon:21659 Mon 11 Mar 2019 12:16:36 AEDT ]]> Mood and anxiety disorders precede development of functional gastrointestinal disorders in patients but not in the population /manager/Repository/uon:34348 Mon 04 Mar 2019 14:57:54 AEDT ]]> The mucosal immune system: master regulator of bidirectional gut-brain communications /manager/Repository/uon:34349 Mon 04 Mar 2019 14:57:53 AEDT ]]> Emerging evidence that irritable bowel syndrome & functional dyspepsia are microbial diseases (editorial) /manager/Repository/uon:35708 Indian Journal of Medical Research, 149, April 2019, pp 437-440.]]> Fri 25 Oct 2019 15:19:19 AEDT ]]> The clinical academic workforce in Australia and New Zealand: report on the second binational summit to implement a sustainable training pathway /manager/Repository/uon:34691 Fri 12 Apr 2019 14:00:40 AEST ]]> Roles of healthcare professionals in the management of chronic gastrointestinal diseases with a focus on primary care: A systematic review /manager/Repository/uon:36862 Fri 10 Jul 2020 19:14:48 AEST ]]> Pharmacists' confidence in managing patients with inflammatory bowel disease /manager/Repository/uon:36857 Fri 10 Jul 2020 19:14:46 AEST ]]> Polymorphisms of 5-HTT LPR and GNβ3 825C>T and response to antidepressant treatment in functional dyspepsia: a study from the functional dyspepsia treatment trial /manager/Repository/uon:34107 T CC genotype has been previously linked to FD and TT genotype to antidepressant response in depression. The ss genotype of the 5-HTT LPR variant of the serotonin transporter gene (SLC6A4) has been linked to selective serotonin reuptake inhibitor (SSRI) response. We aimed to examine whether GNβ3 825C>T and 5-HTT LPR polymorphisms result in differential treatment effects in FD patients receiving antidepressant therapy. Methods: Participants were randomized to receive placebo, 50 mg AMI, or 10 mg escitalopram (ESC). The primary end point was adequate relief for ≥5 weeks of the last 10 weeks. Genotyping of GNβ3 825C>T and 5-HTT LPR was performed utilizing PCR-based methods. Results: GNβ3 825C>T and 5-HTT LPR genotype data were available for 256 (88%) and 246 (84%) patients, respectively. Both polymorphisms were in Hardy-Weinberg equilibrium. In tests for differential treatment, neither 5-HTT LPR nor GNβ3 825C>T genotype influenced response to therapy (P=0.89 and P=0.54, respectively). Although there was a tendency for a more favorable response to ESC in the SS/LS genotype compared to the LL genotype groups (40% vs. 31% reporting adequate relief of FD symptoms) among those in the ESC treatment arm, this was not significant (P=0.43). Conclusions: GNβ3 825C>T and 5-HTT LPR genetic variants do not alter treatment response to tricyclic and SSRI antidepressants in FD.]]> Fri 08 Feb 2019 10:43:58 AEDT ]]> Women and functional dyspepsia /manager/Repository/uon:30117 Fri 01 May 2020 07:02:02 AEST ]]>